Officially introduced to biopharmaceutical customers in late 2010, Molly was designed to offer not only a number of enhanced device features to benefit patients, but also establish an alternative business model that makes more sense for customers and allows them to get their product to market even faster. Some key design features of Molly include compact size, permanently hidden needle, locking needle shield, and a simple 2-step operation with integrated safety features. The concept of patients using an auto injector to self-administer injections safely in the comfort of their own home is a significant contribution to advancing patient lifestyles and also their quality of life (QOL). The unique design features that the Molly device utilize help to further enhance patient compliance by focusing on convenience, safety and offering a device that end users are comfortable with using.
Although the commercial applications of the Molly auto injector will depend on the corresponding biopharmaceutical customer, it is likely to be intended for therapeutic areas that require frequent injections either at home or in a clinical environment, leading to high volume demands. Auto injectors are becoming more commonly used to deliver medications that treat a variety of therapeutic areas such as RA, Oncology, Diabetes, MS and many others. As a result, mass production will be required to support the demand for this device and in turn stimulate various industrial activities to support the manufacturing processes required for development.
The achievements of Molly, SHL’s first pre-configured auto injector, have raised the bar for similar devices and SHL will continue to invest in project and design teams to bring to the industry new innovations that will benefit patients throughout the world.